Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer

Óscar Arrieta(Instituto Nacional de Cancerología), Rafael Rosell(Hospital Universitario Dexeus), Diego A. Díaz-García, Marco Polo Peralta Álvarez, Beatriz Mota-Vega, Zyanya Lucía Zatarain-Barrón, Andrés F. Cardona(Addario Lung Cancer Medical Institute), Christian Rolfo(Icahn School of Medicine at Mount Sinai), Fernando Aldaco(Centro Medico Nacional Siglo XXI), Raquel Gerson(Centro Médico ABC), Masao Yamamoto Ramos, Feliciano Barrón

JAMA Oncology

April 9, 2020

10.1001/jamaoncol.2020.0409

Cited by 153

Related Papers

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

|The Lancet Oncology|2012|5.5k

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2019|3.3k

Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer

|New England Journal of Medicine|2017|2.4k

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

|New England Journal of Medicine|2009|2.4k

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

|Journal of Clinical Oncology|2004|1.7k